---
title: 'Ozempic vs Mounjaro vs Pepio: Key Differences & How to Track Your GLP‑1 Routine'
date: '2026-09-11'
slug: ozempic-vs-mounjaro-vs-pepio-key-differences-how-to-track-your-glp1-routine
description: Compare Ozempic, Mounjaro, and Pepio GLP‑1 tracker. Learn mechanisms,
  dosing, side‑effects, and how to log injections, symptoms, and weight loss.
updated: '2026-09-11'
author: Dr. Benjamin Paul
site: 'Pepio: GLP-1 Peptide Tracker'
---

# Ozempic vs Mounjaro vs Pepio: Key Differences & How to Track Your GLP‑1 Routine

## Ozempic vs Mounjaro vs Pepio: Why Comparing These Options Matters

If you searched for an ozempic vs mounjaro comparison guide with tracker recommendation, this section starts that conversation. At a high level, tirzepatide (Mounjaro) shows larger average A1C and weight reductions than semaglutide (Ozempic) ([Drugs.com – Mounjaro vs Ozempic Comparison](https://www.drugs.com/medical-answers/mounjaro-ozempic-compare-3571637/)). Clinical analyses across trials also show tirzepatide’s advantage for glycemic control and weight loss, but higher doses increase gastrointestinal side‑effect risk ([Drugs.com – Mounjaro vs Ozempic Comparison](https://www.drugs.com/medical-answers/mounjaro-ozempic-compare-3571637/)). Both medications act through GLP‑1 pathways, and the class mechanisms are reviewed in clinical literature ([StatPearls – GLP-1 Receptor Agonists](https://www.ncbi.nlm.nih.gov/books/NBK551568/)). Beyond efficacy, the practical issue is routine management. Missed shots, scattered notes, and unclear symptom logs hide important patterns. Pepio helps you keep dose history, shot dates, symptoms, injection sites, and weight progress in one place. People using Pepio can turn scattered records into clear notes for follow‑ups with their clinician. Read on for a side‑by‑side comparison and a tracking‑first recommendation that centers practical routine management.

## Comparison Criteria: What to Evaluate When Choosing a GLP‑1 Solution

These six GLP‑1 medication comparison criteria help you evaluate options and track a routine consistently. Use them to compare drugs like Ozempic and Mounjaro, and to choose what to log in your tracker. The phrase "GLP‑1 medication comparison criteria" summarizes what to focus on when deciding and tracking.

- **Mechanism of action** — The drug’s target explains differences in effect and side‑effect patterns ([StatPearls review](https://www.ncbi.nlm.nih.gov/books/NBK551568/)).
- **Dosing schedule** — Frequency and titration affect how often you log doses and set reminders ([StatPearls review](https://www.ncbi.nlm.nih.gov/books/NBK551568/)).
- **Typical side‑effects** — Know common GI effects so you can track timing and symptom severity ([e‑DMJ safety review](https://www.e-dmj.org/journal/view.php?number=2974)).
- **Weight‑loss efficacy** — Relative effectiveness influences expectations and progress metrics to record ([StatPearls review](https://www.ncbi.nlm.nih.gov/books/NBK551568/)).
- **Tracking convenience** — Native dashboards vary, so external trackers reduce friction and centralize logs ([Wolters Kluwer](https://www.wolterskluwer.com/en/expert-insights/glp-1-medications-and-weight-loss-help-patients-navigate-beyond-trends)).
- **Safety & regulatory notes** — Label guidance and approvals affect what you document and when to consult your clinician.

Pepio helps you apply these criteria by keeping dose history, symptoms, and reminders in one place. Pepio’s approach makes comparing options and maintaining a clean routine easier before and after clinic visits.

## Option 1 – Pepio GLP‑1 & Peptide Tracker: Your All‑in‑One Routine Manager

Pepio helps you treat tracking as the primary task, not an afterthought. It centralizes injection logs (dose, date, site, symptoms), reminders, symptom entries including appetite/food‑noise notes, weight progress tied to dose history, injection‑site rotation, and free web calculators for conversions and vial math. Download the free Pepio iOS app on the Apple App Store, or use Pepio’s 24 free, no‑sign‑up web tools in any browser. Pepio is privacy‑first—calculations run locally and Pepio doesn’t store personal data on its servers. Tracking first gives clear outcomes. You spend less time reconstructing history. You arrive at clinician visits with organized notes. You stop guessing whether a shot happened or which site you used. These practical benefits match broader advice to move tracking beyond fragmented notes and trends ([Wolters Kluwer GLP-1 Tracking Insights](https://www.wolterskluwer.com/en/expert-insights/glp-1-medications-and-weight-loss-help-patients-navigate-beyond-trends)). Compared to generic lists or memory, Pepio meets comparison criteria from a tracking-first perspective. It organizes dose history and schedules so shot day is consistent. It logs symptoms and food noise so patterns become visible. It records injection sites so rotation is easy to follow. It provides calculators to keep vial math and unit conversions accessible without extra spreadsheets. This stays strictly organizational and not clinical. Research shows consumer-grade GLP-1 apps can be useful, though evidence remains limited ([Medscape analysis of GLP-1 apps (2026)](https://www.medscape.com/viewarticle/glp-1-apps-helpful-companions-or-false-sense-security-2026a1000i9n)). Users often spend less time reconstructing history when everything is logged in one place. Pepio's approach focuses on simple, repeatable logging so daily routines require less effort. Learn more about Pepio's approach to GLP‑1 routine organization and consider tracking your next shot there to keep dose history, symptoms, and progress in one place. Pepio is for organization and self-tracking only. Pepio does not provide medical advice, diagnosis, or dosing recommendations. Always follow instructions from your clinician, prescriber, or pharmacist.

## Option 2 – Ozempic (semaglutide): Mechanism, Dosing, and Tracking Needs

Semaglutide (branded as Ozempic) is a GLP‑1 receptor agonist that mimics the body’s GLP‑1 hormone. It enhances glucose‑dependent insulin release, suppresses glucagon, and slows gastric emptying, which together affect blood sugar and appetite ([StatPearls](https://www.ncbi.nlm.nih.gov/books/NBK603723/)).

The approved Ozempic schedule is a once‑weekly subcutaneous injection. Treatment commonly starts at 0.25 mg weekly for four weeks, increases to 0.5 mg, and may be titrated to 1 mg and up to 2 mg (label maximum) as indicated, per the prescribing information ([FDA Prescribing Information – Ozempic (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf)). Patients should follow their clinician’s instructions for any dose changes.

Gastrointestinal side effects are the most reported adverse events. Nausea occurs in about 20–30% of users, while constipation appears in roughly 10–15% ([FDA Prescribing Information – Ozempic (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf)). In long‑term trials, higher‑dose semaglutide formulations produced substantial weight loss; for example, the STEP 1 trial of 2.4 mg semaglutide (marketed as Wegovy for obesity) found a mean 14.9% weight reduction at 68 weeks with high rates of clinically meaningful weight loss ([NEJM STEP 1 Trial – Semaglutide Weight Loss (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183)). Use trial results only as context, not individual expectations.

Ozempic does not include a built‑in patient tracking dashboard. Many people rely on calendars, notes, or third‑party tools instead ([Drugs.com – Ozempic History (2024)](https://www.drugs.com/history/ozempic.html)). That gap makes it useful to log dose date, dose amount, injection site, post‑shot symptoms, and weight trends. A separate tracker also helps spot patterns around shot day and dose changes.

Pepio helps users keep that practical record so shot history stays clear and accessible. Teams using Pepio experience simpler dose history review and cleaner symptom notes before clinician visits. Learn more about Pepio’s approach to tracking GLP‑1 routines and consider saving your next shot in Pepio for better organization. Pepio is for organization and self‑tracking only. Pepio does not provide medical advice, dosing recommendations, or treatment guidance. Always follow instructions from your clinician, prescriber, pharmacist, or medication label.

## Option 3 – Mounjaro (tirzepatide): Mechanism, Dosing, and Tracking Needs

Mounjaro (tirzepatide) combines glucose‑dependent insulinotropic polypeptide (GIP) and GLP‑1 receptor agonism, offering dual action on appetite and insulin sensitivity compared with GLP‑1–only drugs (see mechanism overview in StatPearls and summary comparisons on Drugs.com). The dual GIP/GLP‑1 mechanism helps explain the higher potency seen in trials and real‑world reports ([StatPearls](https://www.ncbi.nlm.nih.gov/books/NBK585056/); [Drugs.com comparison](https://www.drugs.com/medical-answers/mounjaro-ozempic-compare-3571637/)).

The approved dosing is once‑weekly subcutaneous injection. Treatment typically starts at 2.5 mg and increases by 2.5 mg approximately every four weeks, with a labeled maximum of 15 mg once weekly. The FDA prescribing information outlines this titration approach and the rationale for gradual increases to improve tolerability ([FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf)).

Gastrointestinal side effects are the most common adverse events. GI effects are common and tend to increase with dose; nausea, vomiting, and diarrhea are among the most reported symptoms in trials and in the label, with exact rates varying by study and dose ([StatPearls tirzepatide chapter](https://www.ncbi.nlm.nih.gov/books/NBK585056/)). Fatigue is reported less often but can appear during titration.

Efficacy signals are strong in obesity trials: SURMOUNT‑1 reported ~20–22% mean weight reduction at ~72 weeks with 15 mg tirzepatide. In type 2 diabetes trials like SURPASS‑5, tirzepatide produced significant reductions in HbA1c with more modest weight loss compared with the obesity trials ([StatPearls summary of SURPASS results](https://www.ncbi.nlm.nih.gov/books/NBK585056/)).

Regulatory context matters. The FDA label notes rodent findings of thyroid C‑cell tumors and recommends that clinicians consider this risk and monitoring where appropriate ([FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf)). This is part of the safety information prescribers review when choosing therapy.

For users, the practical tracking needs are clear. Log titration dates, exact dose amounts, and any GI symptoms after each shot. Track weight and HbA1c changes alongside dose changes. Pepio helps you record titration histories and symptom timelines so you can see patterns over time. Users using Pepio experience clearer notes for follow‑up visits and fewer guesswork moments about when dose changes happened. Pepio's approach to routine tracking enables organized conversations with your clinician without replacing medical guidance.

Pepio is for organization and self‑tracking only. Pepio does not provide medical advice, dosing recommendations, or clinical decisions. Always follow instructions from your clinician, prescriber, pharmacist, or medication label. Learn more about Pepio’s approach to tracking titration schedules, symptoms, and weight progress if you want a simple way to keep your Mounjaro routine organized.

## Side‑by‑Side Comparison: Pepio Tracker, Ozempic, and Mounjaro

This side‑by‑side summary highlights what each option is and the tradeoffs between tracking needs and clinical treatment.

|  | Pepio | Ozempic | Mounjaro |
|---|---|---|---|
| **Purpose:** | Pepio — a routine tracker for logging shots, reminders, sites, symptoms, and weight progress. Includes AI assistants, exportable logs (CSV/PDF), and custom medication support on iOS. | Ozempic — a prescription GLP‑1 drug used for glycemic control and weight loss. | Mounjaro — a prescription GLP‑1/GIP drug focused on metabolic control and higher weight‑loss potential. |
| **Mechanism:** | Pepio — an organizational tool, not a medication. | Ozempic — a GLP‑1 receptor agonist that affects appetite and glucose (class overview in [StatPearls](https://www.ncbi.nlm.nih.gov/books/NBK551568/)). | Mounjaro — a dual GIP/GLP‑1 agonist with broader metabolic action ([StatPearls](https://www.ncbi.nlm.nih.gov/books/NBK551568/)). |
| **Dosing overview:** | Pepio — tracks the doses you were instructed to take and your schedule. | Ozempic — weekly injectable dosing under prescriber direction. | Mounjaro — weekly injectable dosing with clinician‑guided titration. |
| **Typical side effects:** | Pepio — lets you record and review side effects over time. | Ozempic — gastrointestinal effects occur most often, including nausea and diarrhea; rates vary by agent ([Drugs.com comparison](https://www.drugs.com/medical-answers/mounjaro-ozempic-compare-3571637/)). | Mounjaro — gastrointestinal effects occur most often, including nausea and diarrhea; rates vary by agent ([Drugs.com comparison](https://www.drugs.com/medical-answers/mounjaro-ozempic-compare-3571637/)). |
| **Weight‑loss outcomes (trial level):** | Pepio — not applicable. | Semaglutide at 2.4 mg (Wegovy) shows roughly a ~15% mean weight loss in higher‑dose studies ([NEJM STEP 1 Trial](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183)). | Tirzepatide trials (SURMOUNT‑1) report roughly ~20–22% average body‑weight reduction in phase‑3 studies. A 2024 synthesis of trials ranks tirzepatide above semaglutide for average weight loss ([Drugs.com overview](https://www.drugs.com/medical-answers/mounjaro-wegovy-ozempic-compare-weight-loss-3570898/)). |
| **Tracking & convenience:** | Pepio centralizes shot logs, reminders, site rotation, symptom notes, and weight charts so you avoid scattered notes. Includes AI assistants, exportable logs, and custom meds support on iOS. | Ozempic — requires external tracking for routine details unless you use a dedicated tracker. | Mounjaro — requires external tracking for routine details unless you use a dedicated tracker. |
| **Safety & regulatory notes:** | Pepio is an organizational app, not medical advice. | Ozempic — prescription drug; dosing and safety details are in prescribing information; discuss with your clinician. | Mounjaro — prescription drug; dosing and safety details are in prescribing information; discuss with your clinician. |

If your main need is to stop relying on memory and build a reliable routine, Pepio is the first choice for tracking. If you need clinical treatment decisions or to compare efficacy, discuss drug options with your prescriber and review trial data like the NEJM study and class summaries linked above. Learn more about Pepio’s approach to organizing GLP‑1 routines and preparing better notes for clinician visits.

In short: Mounjaro tends to show higher average weight‑loss efficacy in trials, but it can come with more gastrointestinal side effects for some people. Ozempic offers a well‑established dosing pattern and predictable weekly scheduling for many users. Choosing between them is a clinician decision. Talk with your prescriber before changing medications or dose schedules.

Tracking makes the difference between guessing and clear records. Log shot dates, dose amounts, injection sites, symptoms, and weight trends so you can spot patterns over weeks. Pepio helps you keep those details in one place so you are not relying on memory or scattered notes.

Apps can help, but they are not a substitute for medical advice. A recent Medscape analysis notes that GLP‑1 apps can be useful companions while also raising concerns about a false sense of security for some users ([Medscape analysis of GLP-1 apps (2026)](https://www.medscape.com/viewarticle/glp-1-apps-helpful-companions-or-false-sense-security-2026a1000i9n)). Use tracking tools to organize what your clinician already told you, not to make dosing decisions.

If you want a practical next step, try organizing one week of records. Save each shot date, note any nausea or appetite changes, and record your weight once a week. Users using Pepio report clearer dose history and simpler prep for follow‑up visits. Pepio's routine-focused approach makes it easier to see trends between shots, symptoms, and weight progress.

To explore more, learn about Pepio and try its free calculators or start a simple shot log on the app ([Pepio GLP‑1 Tracker on the App Store](https://apps.apple.com/app/pepio-glp-1-tracker)). Android users can use Pepio’s free browser tools to access the same calculators, planners, and exportable trackers.

Pepio is for organization and self‑tracking only. It does not provide medical advice, diagnosis, or dosing recommendations. Always follow the guidance from your clinician, prescriber, pharmacist, or medication label.